Preferred Label : Sacituzumab Govitecan;
NCIt synonyms : hRS7-SN38 Antibody Drug Conjugate; RS7-SN38; Sacituzumab Govitecan-hziy;
NCIt definition : An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against
tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the
active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential
antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively
binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively
stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit
DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1
(EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety
of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell
adhesion and its expression is associated with increased cancer growth, aggressiveness
and metastasis.;
UNII : M9BYU8XDQ6;
CAS number : 1491917-83-9;
Drug name : Trodelvy;
Molecule name : IMMU-132; RS7SN38; IMMU 132; RS7 SN38;
Codes from synonyms : 456;
Origin ID : C102783;
UMLS CUI : C4086837;
Automatic exact mappings (from CISMeF team)
CISMeF manual mappings
Currated CISMeF NLP mapping
Semantic type(s)
UMLS correspondences (same concept)
concept_is_in_subset
has_target
is_component_of_chemotherapy_regimen
https://www.has-sante.fr/jcms/p_3537214/fr/trodelvy-sacituzumab-govitecan-cancer-du-sein
2024
false
false
false
France
evaluation of the transparency committee
neoplasm, malignant
Sacituzumab Govitecan
Male Breast Carcinoma
sacituzumab govitecan
breast neoplasms
breast cancer
sacituzumab govitecan
Childhood Breast Carcinoma
---